Can naltrexone be used to treat Graves disease?

Naltrexone is NOT indicated for Graves disease and should not be used for this purpose

Naltrexone has no established role in treating Graves disease or any thyroid disorder. The FDA-approved indications for naltrexone are exclusively for alcohol use disorder and opioid use disorder, where it functions as an opioid receptor antagonist 1.

FDA-Approved Indications

Naltrexone is approved only for:

• Alcohol use disorder: Demonstrated efficacy in reducing drinking days and supporting abstinence when combined with psychosocial interventions 1
• Opioid use disorder: Produces complete blockade of opioid euphoric effects, though compliance remains challenging 2, 1

Evidence Regarding Thyroid Conditions

The only relevant study examining naltrexone and thyroid disease specifically contradicts any therapeutic benefit:

• A 2020 Norwegian study of 898 patients with hypothyroidism found no association between starting low-dose naltrexone (LDN) and subsequent changes in thyroid hormone requirements 3
• If anything, there was a trend toward increasing levothyroxine consumption with LDN exposure 3
• The authors explicitly concluded: "The results of this study do not support claims of efficacy of LDN in hypothyroidism" 3

Mechanism of Action Incompatibility

Naltrexone's pharmacologic mechanisms are entirely unrelated to thyroid pathophysiology:

• It antagonizes opioid receptors (μ, κ, δ) with no direct thyroid effects 1
• Graves disease is an autoimmune condition caused by thyroid-stimulating immunoglobulins that requires antithyroid medications, radioactive iodine, or thyroidectomy 3
• While some speculate LDN has immunomodulatory properties 4, 5, this remains theoretical with no validated clinical application for autoimmune thyroid disease 3

Clinical Recommendation

For Graves disease, use evidence-based treatments: antithyroid drugs (methimazole, propylthiouracil), radioactive iodine ablation, or thyroidectomy. Naltrexone offers no therapeutic benefit for this condition and diverts patients from effective, guideline-concordant therapy 3.